Haemodynamic management of septic shock

Abstract

Septic shock is a significant challenge in the management of patients with burns and traumatic injuries when complicated by infection, necessitating prompt and effective haemodynamic support. This review provides a comprehensive overview of current strategies for vasopressor and fluid management in septic shock, with the aim to optimize patient outcomes. With regard to vasopressor management, we elaborate on the pharmacologic profiles and clinical applications of catecholamines, vasopressin derivatives, angiotensin II, and other vasoactive agents. Noradrenaline remains central to septic shock management. The addition of vasopressin, when sequentially added to noradrenaline, offers a non-catecholaminergic vasoactive effect with some clinical benefits and risks of adverse effects. Emerging agents such as angiotensin II and hydroxocobalamin are highlighted for their roles in catecholamine-resistant vasodilatory shock. Next, for fluid management, crystalloids are currently preferred for initial resuscitation, with balanced crystalloids showing benefits over saline. The application of albumin in septic shock warrants further research. High-quality evidence does not support large-volume fluid resuscitation, and an individualized strategy based on haemodynamic parameters, including lactate clearance and capillary refill time, is recommended. The existing knowledge suggests that early vasopressor initiation, particularly noradrenaline, may be critical in cases where fluid resuscitation takes inadequate effect. Management of refractory septic shock remains challenging, with novel agents like angiotensin II and methylene blue showing potential in recent studies. In conclusion, Further research is needed to optimize haemodynamic management of septic shock, particularly in developing novel vasopressor usage and fluid management approaches.

Keywords

Haemodynamic / Management / Shock / Sepsis

References

[1] Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C. et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021; 47: 1181-247. https://doi.org/10.1007/s00134-021-06506-y.

[2] Gordon AC, Alipanah-Lechner N, Bos LD, Dianti J, Diaz JV, Finfer S. et al. From ICU syndromes to ICU subphenotypes: consensus report and recommendations for developing precision medicine in the ICU. Am J Respir Crit Care Med. 2024; 210: 155-66. https://doi.org/10.1164/rccm.202311-2086SO.

[3] Brown SM, Lanspa MJ, Jones JP, Kuttler KG, Li Y, Carlson R. et al. Survival after shock requiring high-dose vasopressor therapy. Chest. 2013; 143: 664-71. https://doi.org/10.1378/chest.12-1106.

[4] Annane D, Vignon P, Renault A, Bollaert P-E, Charpentier C, Martin C. et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet. 2007; 370: 676-84. https://doi.org/10.1016/S0140-6736(07)61344-0.

[5] De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C. et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010; 362: 779-89. https://doi.org/10.1056/NEJMoa0907118.

[6] Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ. et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008; 358: 877-87. https://doi.org/10.1056/NEJMoa067373.

[7] Abu Sardaneh A, Goradia S, Narayan SW, Penm J, McLachlan AJ, Patanwala AE. Dose equivalence between metaraminol and norepinephrine in critical care. Br J Clin Pharmacol. 2022; 88: 303-10. https://doi.org/10.1111/bcp.14969.

[8] Santer P, Anstey MH, Patrocínio MD, Wibrow B, Teja B, Shay D. et al. Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomised clinical trial. Intensive Care Med. 2020; 46: 1884-93. https://doi.org/10.1007/s00134-020-06216-x.

[9] Costa-Pinto R, Yong Z-T, Yanase F, Young C, Brown A, Udy A. et al. A pilot, feasibility, randomised controlled trial of midodrine as adjunctive vasopressor for low-dose vasopressor-dependent hypotension in intensive care patients: the MAVERIC study. J Crit Care. 2022; 67: 166-71. https://doi.org/10.1016/j.jcrc.2021.11.004.

[10] Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M. et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA. 2016; 316: 509-18. https://doi.org/10.1001/jama.2016.10485.

[11] Laterre P-F, Berry SM, Blemings A, Carlsen JE, François B, Graves T. et al. Effect of selepressin vs placebo on ventilator-and vasopressor-free days in patients with septic shock: the SEPSIS-ACT randomized clinical trial. JAMA. 2019; 322: 1476-85. https://doi.org/10.1001/jama.2019.14607.

[12] Liu ZM, Chen J, Kou Q, Lin Q, Huang X, Tang Z. et al. Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial. Intensive Care Med. 2018; 44: 1816-25. https://doi.org/10.1007/s00134-018-5267-9.

[13] Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H. et al. Angiotensin II for the treatment of Vasodilatory shock. N Engl J Med. 2017; 377: 419-30. https://doi.org/10.1056/NEJMoa1704154.

[14] Ibarra-Estrada M, Kattan E, Aguilera-Gonzalez P, Sandoval-Plascencia L, Rico-Jauregui U, Gomez-Partida CA. et al. Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial. Crit Care. 2023; 27: 110. https://doi.org/10.1186/s13054-023-04397-7.

[15] Patel JJ, Willoughby R, Peterson J, Carver T, Zelten J, Markiewicz A. et al. High-dose intravenous Hydroxocobalamin (vitamin B12) in septic shock: a double-blind, allocation-concealed, placebo-controlled single-Center pilot randomized controlled trial (the IV-HOCSS trial). Chest. 2022; 163: 303-12. https://doi.org/10.1016/j.chest.2022.09.021.

[16] Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R. et al. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med. 2018; 378: 797-808. https://doi.org/10.1056/NEJMoa1705835.

[17] Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot J-P, Siami S. et al. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med. 2018; 378: 809-18. https://doi.org/10.1056/NEJMoa1705716.

[18] Persichini R, Silva S, Teboul J-L, Jozwiak M, Chemla D, Richard C. et al. Effects of norepinephrine on mean systemic pressure and venous return in human septic shock. Crit Care Med. 2012; 40: 3146-53. https://doi.org/10.1097/CCM.0b013e318260c6c3.

[19] Monnet X, Jabot J, Maizel J, Richard C, Teboul J-L. Norepinephrine increases cardiac preload and reduces preload dependency assessed by passive leg raising in septic shock patients. Crit Care Med. 2011; 39: 689-94. https://doi.org/10.1097/CCM.0b013e318206d2a3.

[20] Ospina-Tascón GA, Aldana JL, García Marín AF, Calderón-Tapia LE, Marulanda A, Escobar EP. et al. Immediate norepinephrine in Endotoxic shock: effects on regional and microcirculatory flow. Crit Care Med. 2023; 51: e157-68. https://doi.org/10.1097/CCM.0000000000005885.

[21] Wieruszewski PM, Khanna AK. Vasopressor choice and timing in Vasodilatory shock. Crit Care. 2022; 26: 76. https://doi.org/10.1186/s13054-022-03911-7.

[22] Sato R, Duggal A, Sacha GL, Rudoni MA, Yataco AC, Khanna AK. et al. The relationship between norepinephrine equivalent dose of vasopressors within 24 hours from the onset of septic shock and In-hospital mortality rate. Chest. 2023; 163: 148-51. https://doi.org/10.1016/j.chest.2022.07.018.

[23] Auchet T, Regnier MA, Girerd N, Levy B. Outcome of patients with septic shock and high-dose vasopressor therapy. Ann Intensive Care. 2017; 7: 43. https://doi.org/10.1186/s13613-017-0261-x.

[24] Kotani Y, Belletti A, Da UJ, Salvati S, Landoni G. Norepinephrine dose should be reported as base equivalence in clinical research manuscripts. J Cardiothorac Vasc Anesth. 2023; 37: 1523-4. https://doi.org/10.1053/j.jvca.2023.05.013.

[25] Wieruszewski PM, Leone M, Kaas-Hansen BS, Dugar S, Legrand M, McKenzie CA. et al. Position paper on the reporting of norepinephrine formulations in critical care from the Society of Critical Care Medicine and European Society of Intensive Care Medicine Joint Task Force. Crit Care Med. 2024; 52: 521-30. https://doi.org/10.1097/CCM.0000000000006176.

[26] Kotani Y, Landoni G, Belletti A, Khanna AK. Response to: norepinephrine formulation for equivalent vasopressive score. Crit Care. 2023; 27: 125. https://doi.org/10.1186/s13054-023-04404-x.

[27] Leone M, Goyer I, Levy B, Dunser MW, Asfar P, Jentzer JC. Dose of norepinephrine: the devil is in the details. Intensive Care Med. 2022; 48: 638-40. https://doi.org/10.1007/s00134-022-06652-x.

[28] Lubberding AF, Thomsen MB. Low-dose adrenaline reduces blood pressure acutely in anesthetized pigs through a beta2-adrenergic pathway. J Cardiovasc Pharmacol. 2019; 74: 38-43. https://doi.org/10.1097/FJC.0000000000000682.

[29] Cui J, Wei X, Lv H, Li Y, Li P, Chen Z. et al. The clinical efficacy of intravenous IgM-enriched immunoglobulin (pentaglobin) in sepsis or septic shock: a meta-analysis with trial sequential analysis. Ann Intensive Care. 2019; 9: 27. https://doi.org/10.1186/s13613-019-0501-3.

[30] Legrand M, van der Horst ICC, De Jong A. Serial lactate measurements to guide resuscitation: more evidence not to? Intensive Care Med. 2024; 50: 728-30. https://doi.org/10.1007/s00134-024-07411-w.

[31] Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J. et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med. 2008; 34: 2226- 34. https://doi.org/10.1007/s00134-008-1219-0.

[32] Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and new Zealand Intensive Care Society (ANZICS) clinical trials group. Lancet. 2000; 356: 2139-43.

[33] De Backer D, Aldecoa C, Njimi H, Vincent JL.Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis∗. Crit Care Med. 2012; 40: 725-30. https://doi.org/10.1097/CCM.0b013e31823778ee.

[34] Morelli A, Ertmer C, Rehberg S, Lange M, Orecchioni A, Laderchi A. et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Crit Care. 2008; 12: R143. https://doi.org/10.1186/cc7121.

[35] Vail E, Gershengorn HB, Hua M, Walkey AJ, Rubenfeld G, Wunsch H. Association between US norepinephrine shortage and mortality among patients with septic shock. JAMA. 2017; 317: 1433-42. https://doi.org/10.1001/jama.2017.2841.

[36] Harrison DC, Chidsey CA, Braunwald E. Studies on the mechanism of action of Metaraminol (Aramine). Ann Intern Med. 1963; 59: 297-305. https://doi.org/10.7326/0003-4819-59-3-297.

[37] Costa-Pinto R, Neto AS, Matthewman MC, Osrin D, Liskaser G, Li J. et al. Dose equivalence for metaraminol and noradrenaline-a retrospective analysis. J Crit Care. 2024; 80: 154430. https://doi.org/10.1016/j.jcrc.2023.154430.

[38] Natalini G, Schivalocchi V, Rosano A, Taranto M, Pletti C, Bernardini A. Norepinephrine and metaraminol in septic shock: a comparison of the hemodynamic effects. Intensive Care Med. 2005; 31: 634-7. https://doi.org/10.1007/s00134-005-2607-3.

[39] Landry DW, Levin HR, Gallant EM, Ashton RC, Jr, Seo S, ’Alessandro D D. et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997; 95: 1122-5. https://doi.org/10.1161/01.CIR.95.5.1122.

[40] McIntyre WF, Um KJ, Alhazzani W, Lengyel AP, Hajjar L, Gordon AC. et al. Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines alone with atrial fibrillation in patients with distributive shock: a systematic review and meta-analysis. JAMA. 2018; 319: 1889-900. https://doi.org/10.1001/jama.2018.4528.

[41] Nagendran M, Russell JA, Walley KR, Brett SJ, Perkins GD, Hajjar L. et al. Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials. Intensive Care Med. 2019; 45: 844-55. https://doi.org/10.1007/s00134-019-05620-2.

[42] Russell JA, Vincent J-L, Kjølbye AL, Olsson H, Blemings A, Spapen H. et al. Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. Crit Care. 2017; 21: 213. https://doi.org/10.1186/s13054-017-1798-7.

[43] Lange M, Ertmer C, Westphal M. Vasopressin vs. terlipressin in the treatment of cardiovascular failure in sepsis. Intensive Care Med. 2008; 34: 821-32. https://doi.org/10.1007/s00134-007-0946-y.

[44] Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z. et al. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care. 2014; 18: 534. https://doi.org/10.1186/s13054-014-0534-9.

[45] Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol. 1993; 45: 367-74. https://doi.org/10.1016/0006-2952(93)90072-5.

[46] Memis D, Karamanlioglu B, Yuksel M, Gemlik I, Pamukcu Z. The influence of methylene blue infusion on cytokine levels during severe sepsis. Anaesth Intensive Care. 2002; 30: 755-62. https://doi.org/10.1177/0310057X0203000606.

[47] Juffermans NP, Vervloet MG, Daemen-Gubbels CRG, Binnekade JM, de Jong M, Groeneveld ABJ. A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock. Nitric Oxide. 2010; 22: 275-80. https://doi.org/10.1016/j.niox.2010.01.006.

[48] Martino EA, Winterton D, Nardelli P, Pasin L, Calabrò MG, Bove T. et al. The blue coma: the role of methylene blue in unexplained coma after cardiac surgery. J Cardiothorac Vasc Anesth. 2016; 30: 423-7. https://doi.org/10.1053/j.jvca.2015.09.011.

[49] Vincent JL, Zhang H, Szabo C, Preiser JC. Effects of nitric oxide in septic shock. Am J Respir Crit Care Med. 2000; 161: 1781-5. https://doi.org/10.1164/ajrccm.161.6.9812004.

[50] Zhang H, Moochhala SM, Bhatia M. Endogenous hydrogen sulfide regulates inflammatory response by activating the ERK pathway in polymicrobial sepsis. J Immunol. 2008; 181: 4320-31. https://doi.org/10.4049/jimmunol.181.6.4320.

[51] Ortoleva J, Shapeton AD. Seeing red: Hydroxocobalamin and result interference. J Cardiothorac Vasc Anesth. 2023; 37: 1339-42. https://doi.org/10.1053/j.jvca.2023.03.017.

[52] Li R, Ye JJ, Gan L, Zhang M, Sun D, Li Y. et al. Traumatic inflammatory response: pathophysiological role and clinical value of cytokines. Eur J Trauma Emerg Surg. 2023; 50: 1313-30. https://doi.org/10.1007/s00068-023-02388-5.

[53] Udy AA, Roberts JA, Lipman J, Blot S. The effects of major burn related pathophysiological changes on the pharmacokinetics and pharmacodynamics of drug use: an appraisal utilizing antibiotics. Adv Drug Deliv Rev. 2018; 123: 65-74. https://doi.org/10.1016/j.addr.2017.09.019.

[54] Soussi S, Depret F, Benyamina M, Legrand M. Early hemodynamic Management of Critically ill burn patients. Anesthesiology. 2018; 129: 583-9. https://doi.org/10.1097/ALN.0000000000002314.

[55] Chappell D, Bruegger D, Potzel J, Jacob M, Brettner F, Vogeser M, et al. Hypervolemia increases release of atrial natriuretic peptide and shedding of the endothelial glycocalyx. Crit Care. 2014; 18: 538. https://doi.org/10.1186/s13054-014-0538-5.

[56] Kumar AB, Andrews W, Shi Y, Shotwell MS, Dennis S, Wanderer J. et al. Fluid resuscitation mediates the association between inhalational burn injury and acute kidney injury in the major burn population. J Crit Care. 2017; 38: 62-7. https://doi.org/10.1016/j.jcrc.2016.10.008.

[57] Payen D, de Pont AC, Sakr Y, Spies C, Reinhart K, Vincent JL. et al. A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care. 2008; 12: R74. https://doi.org/10.1186/cc6916.

[58] Udy AA, Roberts JA, Shorr AF, Boots RJ, Lipman J. Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients. Crit Care. 2013; 17: R35. https://doi.org/10.1186/cc12544.

[59] Knabl JS, Bauer W, Andel H, Schwendenwein I, Dado PF, Mittlbock M. et al. Progression of burn wound depth by systemical application of a vasoconstrictor: an experimental study with a new rabbit model. Burns. 1999; 25: 715-21. https://doi.org/10.1016/S0305-4179(99)00086-8.

[60] Knappskog K, Andersen NG, Guttormsen AB, Onarheim H, Almeland SK, Beitland S. Vasoactive and/or inotropic drugs in initial resuscitation of burn injuries: a systematic review. Acta Anaesthesiol Scand. 2022; 66: 795-802. https://doi.org/10.1111/aas.14095.

[61] Crystalloid versus Hydroxyethyl Starch Trial Management C.The crystalloid versus hydroxyethyl starch trial: protocol for a multi-Centre randomised controlled trial of fluid resuscitation with 6% hydroxyethyl starch (130/0.4) compared to 0.9% sodium chloride (saline) in intensive care patients on mortality. Intensive Care Med. 2011; 37: 816-23. https://doi.org/10.1007/s00134-010-2117-9.

[62] Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Aneman A,et al. Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med. 2012; 367: 124-34. https://doi.org/10.1056/NEJMoa1204242.

[63] Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004; 350: 2247-56. https://doi.org/10.1056/NEJMoa040232.

[64] Investigators SS, Finfer S, McEvoy S, Bellomo R, McArthur C, Myburgh J. et al. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med. 2011; 37: 86-96. https://doi.org/10.1007/s00134-010-2039-6.

[65] Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M. et al. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med. 2014; 370: 1412-21. https://doi.org/10.1056/NEJMoa1305727.

[66] Sivapalan P, Ellekjaer KL, Perner A, Møller MH, Granholm A, Grønningsæter L. et al. Preferences for albumin use in adult intensive care unit patients with shock: an international survey. Acta Anaesthesiol Scand. 2024; 68: 1234-43. https://doi.org/10.1111/aas.14479.

[67] Brown RM, Wang L, Coston TD, Krishnan NI, Casey JD, Wanderer JP. et al. Balanced crystalloids versus saline in sepsis. A secondary analysis of the SMART clinical trial. Am J Respir Crit Care Med. 2019; 200: 1487-95. https://doi.org/10.1164/rccm.201903-0557OC.

[68] Raghunathan K, Shaw A, Nathanson B, Sturmer T, Brookhart A, Stefan MS. et al. Association between the choice of IV crystalloid and in-hospital mortality among critically ill adults with sepsis∗. Crit Care Med. 2014; 42: 1585-91. https://doi.org/10.1097/CCM.0000000000000305.

[69] Hammond NE, Zampieri FG, Di Tanna GL, Garside T, Adigbli D, Cavalcanti AB. et al. Balanced crystalloids versus saline in critically ill adults-a systematic review with meta-analysis. NEJM Evid. 2022; 1. https://doi.org/10.1056/EVIDoa2100010.

[70] Semler MW, Self WH, Wanderer JP, Ehrenfeld JM, Wang L, Byrne DW. et al. Balanced crystalloids versus saline in critically ill adults. N Engl J Med. 2018; 378: 829-39. https://doi.org/10.1056/NEJMoa1711584.

[71] Weinberg L, Harris L, Bellomo R, Ierino FL, Story D, Eastwood G. et al. Effects of intraoperative and early postoperative normal saline or plasma-Lyte 148(R) on hyperkalaemia in deceased donor renal transplantation: a double-blind randomized trial. Br J Anaesth. 2017; 119: 606-15. https://doi.org/10.1093/bja/aex163.

[72] Khajavi MR, Etezadi F, Moharari RS, Imani F, Meysamie AP, Khashayar P. et al. Effects of normal saline vs. lactated ringer’s during renal transplantation. Ren Fail. 2008; 30: 535-9. https://doi.org/10.1080/08860220802064770.

[73] Bullivant EM, Wilcox CS, Welch WJ. Intrarenal vasoconstriction during hyperchloremia: role of thromboxane. Am J Phys. 1989; 256: F152-7. https://doi.org/10.1152/ajprenal.1989.256.1.F152.

[74] Wilcox CS. Regulation of renal blood flow by plasma chloride. J Clin Invest. 1983; 71: 726-35. https://doi.org/10.1172/JCI110820.

[75] Jaber S, Paugam C, Futier E, Lefrant JY, Lasocki S, Lescot T. et al. Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet. 2018; 392: 31-40. https://doi.org/10.1016/S0140-6736(18)31080-8.

[76] Serpa Neto A, Fujii T, McNamara M, Moore J, Young PJ, Peake S. et al. Sodium bicarbonate for metabolic acidosis in the ICU: results of a pilot randomized double-blind clinical trial. Crit Care Med. 2023; 51: e221-33. https://doi.org/10.1097/CCM.0000000000005955.

[77] National Heart L, Blood Institute P, Early Treatment of Acute Lung Injury Clinical Trials N, Shapiro NI, Douglas IS, Brower RG. et al. Early restrictive or liberal fluid Management for Sepsis-Induced Hypotension. N Engl J Med. 2023; 388: 499-510. https://doi.org/10.1056/NEJMoa2212663.

[78] Meyhoff TS, Moller MH, Hjortrup PB, Cronhjort M, Perner A, Wetterslev J. Lower vs higher fluid volumes during initial Management of Sepsis: a systematic review with meta-analysis and trial sequential analysis. Chest. 2020; 157: 1478-96. https://doi.org/10.1016/j.chest.2019.11.050.

[79] Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H. et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006; 34: 344-53. https://doi.org/10.1097/01.CCM.0000194725.48928.3A.

[80] Fleischmann-Struzek C, Mellhammar L, Rose N, Cassini A, Rudd KE, Schlattmann P. et al. Incidence and mortality of hospital-and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis. Intensive Care Med. 2020; 46: 1552-62. https://doi.org/10.1007/s00134-020-06151-x.

[81] Marik PE, Cavallazzi R. Does the central venous pressure predict fluid responsiveness? An updated meta-analysis and a plea for some common sense. Crit Care Med. 2013; 41: 1774-81. https://doi.org/10.1097/CCM.0b013e31828a25fd.

[82] Kumar A, Anel R, Bunnell E, Habet K, Zanotti S, Marshall S. et al. Pulmonary artery occlusion pressure and central venous pressure fail to predict ventricular filling volume, cardiac performance, or the response to volume infusion in normal subjects. Crit Care Med. 2004; 32: 691-9. https://doi.org/10.1097/01.CCM.0000114996.68110.C9.

[83] Orso D, Paoli I, Piani T, Cilenti FL, Cristiani L, Guglielmo N. Accuracy of Ultrasonographic measurements of inferior vena cava to determine fluid responsiveness: a systematic review and meta-analysis. J Intensive Care Med. 2020; 35: 354-63. https://doi.org/10.1177/0885066617752308.

[84] Monnet X, Marik P, Teboul JL. Passive leg raising for predicting fluid responsiveness: a systematic review and meta-analysis. Intensive Care Med. 2016; 42: 1935-47. https://doi.org/10.1007/s00134-015-4134-1.

[85] Douglas IS, Alapat PM, Corl KA, Exline MC, Forni LG, Holder AL. et al. Fluid response evaluation in sepsis hypotension and shock: a randomized clinical trial. Chest. 2020; 158: 1431-45. https://doi.org/10.1016/j.chest.2020.04.025.

[86] Michard F, Boussat S, Chemla D, Anguel N, Mercat A, Lecarpentier Y. et al. Relation between respiratory changes in arterial pulse pressure and fluid responsiveness in septic patients with acute circulatory failure. Am J Respir Crit Care Med. 2000; 162: 134-8. https://doi.org/10.1164/ajrccm.162.1.9903035.

[87] Marik PE, Cavallazzi R, Vasu T, Hirani A. Dynamic changes in arterial waveform derived variables and fluid responsiveness in mechanically ventilated patients: a systematic review of the literature. Crit Care Med. 2009; 37: 2642-7. https://doi.org/10.1097/CCM.0b013e3181a590da.

[88] Gu WJ, Zhang Z, Bakker J. Early lactate clearance-guided therapy in patients with sepsis: a meta-analysis with trial sequential analysis of randomized controlled trials. Intensive Care Med. 2015; 41: 1862-3. https://doi.org/10.1007/s00134-015-3955-2.

[89] Hernandez G, Ospina-Tascon GA, Damiani LP, Estenssoro E, Dubin A, Hurtado J. et al. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: the ANDROMEDA-SHOCK randomized clinical trial. JAMA. 2019; 321: 654-64. https://doi.org/10.1001/jama.2019.0071.

[90] Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B. et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001; 345: 1368-77. https://doi.org/10.1056/NEJMoa010307.

[91] Investigators P, Rowan KM, Angus DC, Bailey M, Barnato AE, Bellomo R. et al. Early, goal-directed therapy for septic shock-a patient-level meta-analysis. N Engl J Med. 2017; 376: 2223-34. https://doi.org/10.1056/NEJMoa1701380.

[92] Beck V, Chateau D, Bryson GL, Pisipati A, Zanotti S, Parrillo JE. et al. Timing of vasopressor initiation and mortality in septic shock: a cohort study. Crit Care. 2014; 18: R97. https://doi.org/10.1186/cc13868.

[93] Bai X, Yu W, Ji W, Lin Z, Tan S, Duan K. et al. Early versus delayed administration of norepinephrine in patients with septic shock. Crit Care. 2014; 18: 532. https://doi.org/10.1186/s13054-014-0532-y.

[94] Permpikul C, Tongyoo S, Viarasilpa T, Trainarongsakul T, Chakorn T, Udompanturak S. Early use of norepinephrine in septic shock resuscitation (CENSER). A randomized trial. Am J Respir Crit Care Med. 2019; 199: 1097-105. https://doi.org/10.1164/rccm.201806-1034OC.

[95] Tian DH, Smyth C, Keijzers G, Macdonald SP, Peake S, Udy A. et al. Safety of peripheral administration of vasopressor medications: a systematic review. Emerg Med Australas. 2020; 32: 220-7. https://doi.org/10.1111/1742-6723.13406.

[96] Martin C, Viviand X, Leone M, Thirion X. Effect of norepinephrine on the outcome of septic shock. Crit Care Med. 2000; 28: 2758-65. https://doi.org/10.1097/00003246-200008000-00012.

[97] Avni T, Lador A, Lev S, Leibovici L, Paul M, Grossman A. Vasopressors for the treatment of septic shock: systematic review and meta-analysis. PLoS One. 2015; 10: e0129305. https://doi.org/10.1371/journal.pone.0129305.

[98] Vieillard-Baron A. Septic cardiomyopathy. Ann Intensive Care. 2011; 1: 6. https://doi.org/10.1186/2110-5820-1-6.

[99] Gordon AC, Perkins GD, Singer M, McAuley DF, Orme RM, Santhakumaran S. et al. Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med. 2016; 375: 1638-48. https://doi.org/10.1056/NEJMoa1609409.

[100] Sacha GL, Lam SW, Wang L, Duggal A, Reddy AJ, Bauer SR. Association of Catecholamine Dose, lactate, and shock duration at vasopressin initiation with mortality in patients with septic shock. Crit Care Med. 2022; 50: 614-23. https://doi.org/10.1097/CCM.0000000000005317.

[101] Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S. et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013; 310: 1683-91. https://doi.org/10.1001/jama.2013.278477.

[102] Whitehouse T, Hossain A, Perkins GD, Gordon AC, Bion J, Young D. et al. Landiolol and organ failure in patients with septic shock: the STRESS-L randomized clinical trial. JAMA. 2023; 330: 1641-52. https://doi.org/10.1001/jama.2023.20134.

[103] Weiss SL, Peters MJ, Alhazzani W, Agus MSD, Flori HR, Inwald DP. et al. Surviving sepsis campaign international guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in children. Pediatr Crit Care Med. 2020; 21: e52-106. https://doi.org/10.1097/PCC.0000000000002198.

[104] Dunser MW, Festic E, Dondorp A, Kissoon N, Ganbat T, Kwizera A. et al. Recommendations for sepsis management in resource-limited settings. Intensive Care Med. 2012; 38: 557-74. https://doi.org/10.1007/s00134-012-2468-5.

[105] Bellomo R, Forni LG, Busse LW, McCurdy MT, Ham KR, Boldt DW. et al. Renin and survival in patients given angiotensin II for catecholamine-resistant Vasodilatory shock. A clinical trial. Am J Respir Crit Care Med. 2020; 202: 1253-61. https://doi.org/10.1164/rccm.201911-2172OC.

[106] Kotani Y, Belletti A, Maiucci G, Lodovici M, Fresilli S, Landoni G. et al. Renin as a prognostic marker in intensive care and perioperative settings: a scoping review. Anesth Analg. 2024; 138: 929-36. https://doi.org/10.1213/ANE.0000000000006682.

[107] D’Amico F, Pruna A, Putowski Z, Dormio S, Ajello S, Scandroglio AM. et al. Low versus high blood pressure targets in critically ill and surgical patients: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med. 2024; 52: 1427-38. https://doi.org/10.1097/CCM.0000000000006314.

[108] Lamontagne F, Richards-Belle A, Thomas K, Harrison DA, Sadique MZ, Grieve RD. et al. Effect of reduced exposure to vasopressors on 90-day mortality in older critically ill patients with Vasodilatory hypotension: a randomized clinical trial. JAMA. 2020; 323: 938-49. https://doi.org/10.1001/jama.2020.0930.

[109] Panwar R, Tarvade S, Lanyon N, Saxena M, Bush D, Hardie M. et al. Relative hypotension and adverse kidney-related outcomes among critically ill patients with shock. A Multicenter, prospective cohort study. Am J Respir Crit Care Med. 2020; 202: 1407-18. https://doi.org/10.1164/rccm.201912-2316OC.

[110] Nandhabalan P, Ioannou N, Meadows C, Wyncoll D. Refractory septic shock: our pragmatic approach. Crit Care. 2018; 22: 215. https://doi.org/10.1186/s13054-018-2144-4.

[111] Antonucci E, Polo T, Giovini M, Girardis M, Martin-Loeches I, Nielsen ND. et al. Refractory septic shock and alternative wordings: a systematic review of literature. J Crit Care. 2023; 75: 154258. https://doi.org/10.1016/j.jcrc.2023.154258.

[112] Tumlin JA, Murugan R, Deane AM, Ostermann M, Busse LW, Ham KR. et al. Outcomes in patients with Vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. Crit Care Med. 2018; 46: 949-57. https://doi.org/10.1097/CCM.0000000000003092.

[113] Pruna A, Bonaccorso A, Belletti A, Turi S, Di Prima AL, D’Amico F. et al. Methylene blue reduces mortality in critically ill and perioperative patients: a meta-analysis of randomized trials. J Cardiothorac Vasc Anesth. 2023; 38: 268-74. https://doi.org/10.1053/j.jvca.2023.09.037.

[114] Weingartner R, Oliveira E, Oliveira ES, Sant’Anna UL, Oliveira RP, Azambuja LA. et al. Blockade of the action of nitric oxide in human septic shock increases systemic vascular resistance and has detrimental effects on pulmonary function after a short infusion of methylene blue. Braz J Med Biol Res. 1999; 32: 1505-13. https://doi.org/10.1590/S0100-879X1999001200009.

[115] Gachot B, Bedos JP, Veber B, Wolff M, Regnier B. Short-term effects of methylene blue on hemodynamics and gas exchange in humans with septic shock. Intensive Care Med. 1995; 21: 1027-31. https://doi.org/10.1007/BF01700666.

[116] Kirov MY, Evgenov OV, Evgenov NV, Egorina EM, Sovershaev MA, Sveinbjornsson B. et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med. 2001; 29: 1860-7. https://doi.org/10.1097/00003246-200110000-00002.

[117] Annane D. Corticosteroids for severe sepsis: an evidence-based guide for physicians. Ann Intensive Care. 2011; 1: 7. https://doi.org/10.1186/2110-5820-1-7.

[118] Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. et al. Corticosteroids for treating sepsis in children and adults. Cochrane Database Syst Rev. 2019. https://doi.org/10.1002/14651858.CD002243.pub4.

[119] Pirracchio R, Annane D, Waschka Andre K, Lamontagne F, Arabi Yaseen M, Bollaert P-E. et al. Patient-level meta-analysis of low-dose hydrocortisone in adults with septic shock. NEJM Evid. 2023; 2. https://doi.org/10.1056/EVIDoa2300034.

[120] Annane D, Sébille V, Charpentier C, Bollaert P-E, François B, Korach J-M. et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002; 288: 862-71. https://doi.org/10.1001/jama.288.7.862.